“…This specificity was significantly superior to a single measurement strategy for HS-assays, cTnI-Pathfast, cTnI-Ultra and cTnI-Vista. Our results are comparable to those in the literature when considering HS assays [6] , [17] , [18] , [22] , [30] , but also cTnI Access, cTnI-Vista, cTnI-Vitros, cTnI-AQT [5] , [7] , [14] , [30] , and cTnT-AQT [19] , [30] , although comparison is limited because of the sample size of the population and study protocols (some data in the literature is reported for H0-H2). Moreover, the percentage of rule-out patients with these H0-H3 strategies is elevated for all assays.…”